News

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced…
Read More...

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, announced that the first patient has been…
Read More...

Pfizer Inc. announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial ( NCT05842967 ) MONeT (RSV I Mmunizati ONStudy…
Read More...

Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of…
Read More...

GSK Singapore announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab), which may now be used in combination with…
Read More...

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three…
Read More...

Servier announced that the U.S. Food and Drug Administration (FDA) has approved VORANIGO, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated…
Read More...

Sangamo Therapeutics, Inc., a genomic medicine company, announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously…
Read More...

SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving both the small molecule and cell & gene therapy industry, and Rznomics Inc.,…
Read More...

Roche announced that the European Commission (EC) has approved Vabysmo (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO,…
Read More...

Roche announced the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now…
Read More...

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio…
Read More...

Novartis announced that Scemblix (asciminib) has been granted Priority Review status by the US Food and Drug Administration (FDA) for treatment of newly diagnosed adult patients with…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab) across Europe, starting today. Pyzchiva®, developed and registered by…
Read More...

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that its active-immunotherapy candidate, ACI-35.030 (now…
Read More...

Ipsen and Day One Biopharmaceuticals (Day One), announced a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade…
Read More...

Astellas Pharma Inc. and Graduate School of Medicine / Faculty of Medicine, Osaka University announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of…
Read More...

The Phase III ARANOTE trial, investigating NUBEQA (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC),…
Read More...

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, announced the completion of $35 Million Series A+ financing. This round…
Read More...

CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s…
Read More...